EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease

Bryce D Holt, Samuel J Elliott, Rebecca Meyer, Daniela Reyes, Karyn O'Neil, Zhanna Druzina, Swapnil Kulkarni, Beth L Thurberg, Steven G Nadler, Bartholomew A Pederson

Molecular Therapy · 2025-01 · 33 (1) · 235-248

DOI: 10.1016/j.ymthe.2024.11.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-01. Verfasst von Bryce D Holt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Ball State University, Muncie, IN 47306, USA. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, Glycogen, Disease Models, Animal, RNA, Small Interfering. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pompe disease is caused by acid alpha-glucosidase (GAA) deficiency, resulting in lysosomal glycogen accumulation. This disease is characterized by progressive skeletal muscle weakness, respiratory distress, and in the infantile-onset form, cardiomyopathy. The only approved treatment is enzyme replacement therapy (ERT) with human recombinant GAA. While ERT therapy extends life span, residual symptoms remain, with poor muscle uptake and immunogenicity limiting efficacy. We examined a novel Centyrin protein-short interfering ribonucleic acid (siRNA) conjugate targeting CD71 (transferrin receptor type 1, TfR1) and GYS1, a key enzyme involved in glycogen synthesis. Unlike existing ERTs designed to degrade aberrant glycogen deposits observed in Pompe patients, the CD71 Centyrin:Gys1 siRNA is designed to restore glycogen balance by inhibiting glycogen synthesis. To this end, we administered the CD71 Centyrin:Gys1 siRNA conjugate to the 6neo/6neo Pompe mouse model. Once bound to TfR1, siRNA-conjugated Centyrin is internalized into cells to facilitate gene knockdown. We found that treatment with this conjugate significantly reduced GYS1 protein expression, glycogen synthase enzymatic activity, and glycogen levels in muscle. In addition, impaired treadmill exercise performance of male Pompe mice was improved. These data suggest that Centyrin-mediated delivery of Gys1 siRNA may be an effective next generation therapy for late-onset Pompe disease or, in combination with ERT, for infantile-onset Pompe disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIGlycogenDisease Models, AnimalRNA, Small InterferingAnimalsMiceHumansReceptors, TransferrinAntigens, CDMuscle, SkeletalGlycogen Synthase

Stichwörter der Autor:innen

6(neo)/6(neo)CentyrinPompe diseaseextrahepaticglycogenglycogen storage disease type IIglycogen synthasegys1mousesiRNA

Substanzen

GlycogenRNA, Small InterferingReceptors, TransferrinAntigens, CDCD71 antigenGlycogen Synthase

Autor:innen und Institutionen

  • Department of Biology, Ball State University, Muncie, IN 47306, USA.
  • Aro Biotherapeutics, Philadelphia, PA 19106, USA.
  • Beth Thurberg Orphan Science Consulting LLC, Newton, MA 02458, USA.
  • Center for Medical Education, Ball State University, Muncie, IN 47306, USA; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-Muncie, Muncie, IN 47303, USA. Electronic address: bape…

Förderung

  • National Science Foundation

Zitieren

APA

Holt, B. D., Elliott, S. J., Meyer, R., Reyes, D., O'Neil, K., Druzina, Z., Kulkarni, S., Thurberg, B. L., Nadler, S. G., & Pederson, B. A. (2025). A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. Molecular Therapy, 33(1), 235-248. https://doi.org/10.1016/j.ymthe.2024.11.033

Vancouver

Holt BD, Elliott SJ, Meyer R, Reyes D, O'Neil K, Druzina Z, et al. A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. Molecular Therapy. 2025;33(1):235-248. doi:10.1016/j.ymthe.2024.11.033

BibTeX
@article{Holt2025,
  author = {Holt, Bryce D and Elliott, Samuel J and Meyer, Rebecca and Reyes, Daniela and O'Neil, Karyn and Druzina, Zhanna and Kulkarni, Swapnil and Thurberg, Beth L and Nadler, Steven G and Pederson, Bartholomew A},
  title = {A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {1},
  pages = {235--248},
  doi = {10.1016/j.ymthe.2024.11.033}
}
Kostenlos starten →